Peer-influenced content. Sources you trust. No registration required. This is HCN.
Conexiant
A post hoc SURPASS-CVOT analysis associated tirzepatide with fewer six-component cardiorenal events than dulaglutide in patients with type 2 diabetes and established ASCVD.
Cardiology May 5th 2026